{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:11:48Z","timestamp":1790359908958,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"US"},{"DOI":"10.13039\/501100001279","name":"Great Ormond Street Hospital Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"EPSRC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013120","name":"European Medicines Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013120","id-type":"DOI","asserted-by":"publisher"}]},{"name":"UK"},{"name":"U.S NIH"},{"DOI":"10.13039\/501100011963","name":"European Academy of Neurology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.neuropharm.2019.107861","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T02:01:58Z","timestamp":1574474518000},"page":"107861","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?"],"prefix":"10.1016","volume":"170","author":[{"given":"J. Helen","family":"Cross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5656-0141","authenticated-orcid":false,"given":"Hannah","family":"Cock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2019.107861_bib1","article-title":"The case for medical cannabis\u2014an essay by M P Barnes","volume":"362","author":"Barnes","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.107861_bib2","first-page":"S252","article-title":"A role of the orphan G\u2010protein coupled receptor in the anti\u2010epileptic properties of cannabidiol","volume":"59","author":"Bazelot","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib3","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1111\/epi.14555","article-title":"Progress report on new antiepileptic drugs: a summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development","volume":"59","author":"Bialer","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib4","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/epi.16093","article-title":"Food effect on pharmacokinetics of cannabidiol oral capsules in adult patients with refractory epilepsy","volume":"60","author":"Birnbaum","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib5","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1001\/jama.2017.11909","article-title":"Labeling accuracy of cannabidiol extracts sold online","volume":"318","author":"Bonn-Miller","year":"2017","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2019.107861_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.seizure.2007.05.019","article-title":"Long-term effects of levetiracetam and topiramate in clinical practice: a head-to-head comparison","volume":"17","author":"Bootsma","year":"2008","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2019.107861_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.tips.2015.08.010","article-title":"Polypharmacology shakes hands with complex aetiopathology","volume":"36","author":"Brodie","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2019.107861_bib8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/molecules23102478","article-title":"Cannabinoid delivery systems for pain and inflammation treatment","volume":"23","author":"Bruni","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.neuropharm.2019.107861_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00406-018-0976-1","article-title":"An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use","volume":"269","author":"Budney","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107861_bib10","series-title":"For the Use of (Cannabidiol) for the Treatment of Seizures Associated with LennoxGastaut Syndrome (LGS) and Dravet Syndrome (DS) in Patients 2 Years of Age and Older","article-title":"Memorandum for new drug application (NDA) 210365","author":"Buracchio","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib11","doi-asserted-by":"crossref","first-page":"7895","DOI":"10.1073\/pnas.0511232103","article-title":"Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression","volume":"103","author":"Carrier","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2019.107861_bib12","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib13","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/14737175.2017.1373019","article-title":"The potential role of cannabinoids in epilepsy treatment","volume":"17","author":"De Caro","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2019.107861_bib14","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107861_bib15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S1474-4422(15)00379-8","article-title":"Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib16","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox\u2013Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.neuropharm.2019.107861_bib17","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2019.107861_bib18","article-title":"US authorities recommend first approval of cannabis derived drug","volume":"361","author":"Dyer","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.107861_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/epi.14608","article-title":"Cannabis-based products for pediatric epilepsy: a systematic review","volume":"60","author":"Elliott","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib20","series-title":"Medicinal Cannabis: How Two Heartbreaking Cases Helped Change Law","author":"Gayle","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/ana.24470","article-title":"Confusing placebo effect with natural history in epilepsy: a big data approach","volume":"78","author":"Goldenholz","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib22","series-title":"Home Secretary Announces Review into Medicinal Cannabis Use","author":"Grierson","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib23","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/add.13941","article-title":"The future of the international drug control system and national drug prohibitions","volume":"113","author":"Hall","year":"2018","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2019.107861_bib24","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-019-1044-x","article-title":"Cannabis and psychosis: are we any closer to understanding the relationship?","volume":"21","author":"Hamilton","year":"2019","journal-title":"Curr. Psychiatr. Rep."},{"key":"10.1016\/j.neuropharm.2019.107861_bib25","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/cbdv.200790152","article-title":"Human cannabinoid pharmacokinetics","volume":"4","author":"Huestis","year":"2007","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.neuropharm.2019.107861_bib26","first-page":"S252","article-title":"Antiseizure properties of cannabidiol are attenuated in the absence of transient receptor potential vanilloid 1 receptors","volume":"59","author":"Jones","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib27","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2019.107861_bib28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/nm.f.1869","article-title":"Endocannabinoid signaling as a synaptic circuit breaker in neurological disease","volume":"14","author":"Katona","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2019.107861_bib29","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1111\/bph.14202","article-title":"Cannabidiol exerts antiepileptic effects by restoring hippocampal interneuron functions in a temporal lobe epilepsy model","volume":"175","author":"Khan","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s40265-018-0992-5","article-title":"Efficacy and safety of cannabidiol in epilepsy: a systematic review and meta-analysis","volume":"78","author":"Lattanzi","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2019.107861_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1528-1157.2000.tb00186.x","article-title":"The value of the number-needed-to-treat method in antiepileptic drug trials","volume":"41","author":"Lesaffre","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00406-019-00979-1","article-title":"Does regular cannabis use affect neuroanatomy? An updated systematic review and meta-analysis of structural neuroimaging studies","volume":"269","author":"Lorenzetti","year":"2019","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.neuropharm.2019.107861_bib33","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/acn3.621","article-title":"A prospective open-label trial of a CBD\/THC cannabis oil in dravet syndrome","volume":"5","author":"McCoy","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ene.12603","article-title":"More than seizures: improving the lives of people with refractory epilepsy","volume":"22","author":"Mula","year":"2014","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib35","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S0140-6736(07)60464-4","article-title":"Development of a rational scale to assess the harm of drugs of potential misuse","volume":"369","author":"Nutt","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107861_bib36","series-title":"Transdermal Cannabidiol (VBD) Gel for the Treatmetn of Focal Epilepsy in Adults","author":"O'brien","year":"2019"},{"key":"10.1016\/j.neuropharm.2019.107861_bib37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.yebeh.2016.11.012","article-title":"Cannabinoids in treatment-resistant epilepsy: a review","volume":"70","author":"O'Connell","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2019.107861_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2018.00759","article-title":"Potential clinical benefits of CBD-rich cannabis extracts over purified CBD in treatment-resistant epilepsy: observational data meta-analysis","volume":"9","author":"Pamplona","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib39","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yebeh.2015.02.043","article-title":"Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy","volume":"45","author":"Press","year":"2015","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2019.107861_bib41","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1371\/journal.pmed.0050166","article-title":"Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy","volume":"5","author":"Rheims","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.neuropharm.2019.107861_bib42","doi-asserted-by":"crossref","first-page":"E96","DOI":"10.1111\/epi.13815","article-title":"Quality of Life in Childhood Epilepsy in pediatric patients enrolled in a prospective, open-label clinical study with cannabidiol","volume":"58","author":"Rosenberg","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2019.107861_bib43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-018-0589-2","article-title":"Long-term safety, tolerability, and efficacy of cannabidiol in children with refractory epilepsy: results from an expanded access program in the US","volume":"33","author":"Sands","year":"2019","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2019.107861_bib44","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jcpt.12235","article-title":"Phytocannabinoids and epilepsy","volume":"40","author":"Santos","year":"2015","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.neuropharm.2019.107861_bib45","series-title":"GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006","author":"Schultz","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib46","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/epi4.12011","article-title":"The right and the wrong with epilepsy and her science","volume":"1","author":"Shorvon","year":"2016","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.neuropharm.2019.107861_bib47","doi-asserted-by":"crossref","unstructured":"Sideli, L., Quigley, H., La Cascia, C., Murray, R. M., Cannabis use and the risk of psychosis and affective disorders. J. Dual Diagnosis. https:\/\/doi.org\/10.1080\/15504263.2019.1674991.","DOI":"10.1080\/15504263.2019.1674991"},{"key":"10.1016\/j.neuropharm.2019.107861_bib48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/jnnp-2017-317168","article-title":"Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence","volume":"89","author":"Stockings","year":"2018","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2019.107861_bib49","article-title":"Composition and use of cannabis extracts for childhood epilepsy in the Australian community","volume":"8","author":"Suraev","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2019.107861_bib50","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.yebeh.2017.02.005","article-title":"An Australian nationwide survey on medicinal cannabis use for epilepsy: history of antiepileptic drug treatment predicts medicinal cannabis use","volume":"70","author":"Suraev","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2019.107861_bib51","series-title":"Long-term Safety and Treatment Effects of Cannabidiol in Children and Adults with Treatment-Resistant Epilepsies: Expanded Access Program Results","author":"Szaflarski","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2019.107861_bib53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/practneurol-2018-002058","article-title":"Cannabis and epilepsy","volume":"18","author":"Thomas","year":"2018","journal-title":"Pract. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib54","article-title":"Medical cannabis will be available on prescription in UK from autumn","volume":"362","author":"Torjesen","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2019.107861_bib55","series-title":"Cannabidiol Tolerance in Children and Adults with Treatment Resistant Epilepsy","author":"Uliel-Sibony","year":"2018"},{"key":"10.1016\/j.neuropharm.2019.107861_bib56","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1001\/jama.2015.6613","article-title":"Cannabinoid dose and label accuracy in edible medical cannabis products","volume":"313","author":"Vandrey","year":"2015","journal-title":"JAMA-J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2019.107861_bib58","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2016.18612","article-title":"The risks of Marijuana use during PregnancyThe risks of Marijuana use during PregnancyThe risks of Marijuana use during pregnancy","volume":"317","author":"Volkow","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.neuropharm.2019.107861_bib59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1001\/jamapsychiatry.2015.3278","article-title":"Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a ReviewEffects of cannabis use on human Behavior Effects of cannabis use on human behavior","volume":"73","author":"Volkow","year":"2016","journal-title":"Jama Psychiatr."},{"key":"10.1016\/j.neuropharm.2019.107861_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fneur.2019.00139","article-title":"Valproate MHRA guidance: limitations and opportunities","volume":"10","author":"Watkins","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.neuropharm.2019.107861_bib61","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.yebeh.2014.12.004","article-title":"Placebo and nocebo responses in drug trials of epilepsy","volume":"43","author":"Zaccara","year":"2015","journal-title":"Epilepsy Behav."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390819304277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:06:20Z","timestamp":1758438380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390819304277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":60,"alternative-id":["S0028390819304277"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107861","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A perspective on cannabinoids for treating epilepsy: Do they really change the landscape?","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107861","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107861"}}